Payment overview · 2025
General Payments
$2,689.86
174 reported records · 28 companies
Healthcare provider profile · identity verified
Curt E Coulter, DO
Allopathic & Osteopathic Physicians|Family Medicine · LAPEER, MI · NPI 1407958572
Verified facts
What the public records show
CMS Open Payments records show Curt E Coulter, DO received $2,689.86 in general payments during 2025 across 174 reported records.
PFIZER INC. accounted for 13.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 45 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 197 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 197 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Eliquis by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $373.33 | 13.9% | 24 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $344.42 | 12.8% | 21 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $240.78 | 8.9% | 26 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $208.51 | 7.8% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $200.73 | 7.5% | 9 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $191.28 | 7.1% | 20 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $182.16 | 6.8% | 16 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $153.93 | 5.7% | 11 | 2025 |
| Teleflex LLC | Unresolved — no canonical attribution shown | $146.94 | 5.5% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $97.62 | 3.6% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $88.46 | 3.3% | 5 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $47.76 | 1.8% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $46.85 | 1.7% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $43.82 | 1.6% | 2 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $42.86 | 1.6% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $38.92 | 1.4% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $31.83 | 1.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $29.43 | 1.1% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $29.09 | 1.1% | 2 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $22.04 | 0.8% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.75 | 0.7% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $18.23 | 0.7% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $17.65 | 0.7% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $16.49 | 0.6% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $16.08 | 0.6% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $14.59 | 0.5% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $13.76 | 0.5% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $13.55 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,676.10 | 173 |
| Education | $13.76 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $220.20 | 13 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $208.51 | 8 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $205.87 | 21 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $183.56 | 21 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $153.93 | 11 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $153.13 | 11 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $153.13 | 11 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $148.83 | 9 | 2025 |
Source payment records
|
|||||
| UROLIFT Normalized: urolift |
Device | Teleflex LLC | $146.94 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $146.66 | 10 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $131.32 | 6 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $103.20 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $101.66 | 7 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $101.13 | 9 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $93.76 | 6 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $88.46 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $87.99 | 4 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $86.64 | 7 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $81.52 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $81.52 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $81.45 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $76.94 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $66.44 | 5 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $59.37 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $57.22 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $57.22 | 5 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $47.76 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $46.85 | 3 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $43.82 | 2 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $42.86 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $38.92 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $29.43 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $29.43 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $29.09 | 2 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $22.04 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $22.04 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $18.75 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $18.23 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $17.65 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $16.49 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $16.08 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $16.08 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $14.22 | 1 | 2025 |
Source payment records
|
|||||
| EOHILIA Normalized: eohilia |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $13.76 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $13.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 101 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 69 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 197 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 66 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 65 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 68 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
17 | 11 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
69 | 19 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
197 | 55 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
101 | 30 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
68 | 18 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
197 | 55 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
66 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
65 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
101 | 30 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 642 | 200 |
| Lisinopril | Lisinopril | 514 | 160 |
| Levothyroxine Sodium | Levothyroxine Sodium | 439 | 129 |
| Gabapentin | Gabapentin | 401 | 86 |
| Trazodone Hcl | Trazodone Hcl | 395 | 107 |
| Omeprazole | Omeprazole | 371 | 100 |
| Meloxicam | Meloxicam | 303 | 95 |
| Amlodipine Besylate | Amlodipine Besylate | 293 | 73 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 292 | 55 |
| Metformin Hcl | Metformin Hcl | 277 | 75 |
| Simvastatin | Simvastatin | 245 | 72 |
| Tramadol Hcl | Tramadol Hcl | 245 | 63 |
| Losartan Potassium | Losartan Potassium | 236 | 64 |
| Hydrochlorothiazide | Hydrochlorothiazide | 222 | 70 |
| Tamsulosin Hcl | Tamsulosin Hcl | 218 | 66 |
| Jardiance | Empagliflozin | 197 | 55 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 187 | 64 |
| Metoprolol Tartrate | Metoprolol Tartrate | 187 | 55 |
| Fluticasone Propionate | Fluticasone Propionate | 175 | 98 |
| Fluoxetine Hcl | Fluoxetine Hcl | 169 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 166 | 42 |
| Prednisone | Prednisone | 158 | 105 |
| Metoprolol Succinate | Metoprolol Succinate | 149 | 52 |
| Famotidine | Famotidine | 145 | 55 |
| Allopurinol | Allopurinol | 142 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 124 | 36 |
| Finasteride | Finasteride | 123 | 33 |
| Alendronate Sodium | Alendronate Sodium | 122 | 29 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 121 | 40 |
| Celecoxib | Celecoxib | 120 | 43 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 109 | 88 |
| Pregabalin | Pregabalin | 107 | 22 |
| Donepezil Hcl | Donepezil Hcl | 102 | 29 |
| Eliquis | Apixaban | 101 | 30 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 99 | 15 |
| Furosemide | Furosemide | 97 | 35 |
| Potassium Chloride | Potassium Chloride | 96 | 24 |
| Buspirone Hcl | Buspirone Hcl | 89 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 88 | 36 |
| Alprazolam | Alprazolam | 88 | 29 |
| Clonazepam | Clonazepam | 85 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 80 | 21 |
| Sertraline Hcl | Sertraline Hcl | 78 | 24 |
| Oxycodone Hcl | Oxycodone Hcl | 73 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 72 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 72 | 16 |
| Montelukast Sodium | Montelukast Sodium | 72 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 71 | 24 |
| Ibuprofen | Ibuprofen | 70 | 31 |
| Carvedilol | Carvedilol | 69 | 25 |
| Farxiga | Dapagliflozin Propanediol | 69 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 68 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 67 | 19 |
| Ozempic | Semaglutide | 66 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 65 | 20 |
| Rybelsus | Semaglutide | 65 | 16 |
| Ezetimibe | Ezetimibe | 61 | 19 |
| Ibandronate Sodium | Ibandronate Sodium | 59 | 27 |
| Spironolactone | Spironolactone | 58 | 15 |
| Bupropion Xl | Bupropion Hcl | 57 | 20 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 54 | 20 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 53 | 16 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 51 | 18 |
| Repatha Sureclick | Evolocumab | 51 | suppressed |
| Xarelto | Rivaroxaban | 51 | suppressed |
| Cephalexin | Cephalexin | 49 | 44 |
| Azithromycin | Azithromycin | 46 | 43 |
| Diclofenac Sodium | Diclofenac Sodium | 46 | 15 |
| Pantoprazole Sodium | Pantoprazole Sodium | 46 | 17 |
| Doxazosin Mesylate | Doxazosin Mesylate | 45 | 13 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 44 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 44 | 12 |
| Januvia | Sitagliptin Phosphate | 43 | 16 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 40 | suppressed |
| Glipizide Er | Glipizide | 39 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 38 | 12 |
| Lovastatin | Lovastatin | 37 | 11 |
| Methocarbamol | Methocarbamol | 36 | 12 |
| Atenolol | Atenolol | 35 | suppressed |
| Ramipril | Ramipril | 35 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 35 | 24 |
| Glipizide | Glipizide | 34 | 11 |
| Trulicity | Dulaglutide | 34 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 33 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 31 | suppressed |
| Mounjaro | Tirzepatide | 31 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 29 | suppressed |
| Nifedipine Er | Nifedipine | 29 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 29 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 28 | suppressed |
| Synthroid | Levothyroxine Sodium | 28 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 24 |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Linzess | Linaclotide | 26 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 26 | suppressed |
| Gemfibrozil | Gemfibrozil | 25 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 24 | 16 |
| Sucralfate | Sucralfate | 24 | 12 |
| Acyclovir | Acyclovir | 23 | 14 |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 21 |
| Nystatin | Nystatin | 23 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 23 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 22 | suppressed |
| Fluconazole | Fluconazole | 21 | 14 |
| Naproxen | Naproxen | 21 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 21 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 19 |
| Terazosin Hcl | Terazosin Hcl | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 19 | suppressed |
| Glimepiride | Glimepiride | 19 | suppressed |
| Humulin R | Insulin Regular, Human | 19 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 19 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Lorazepam | Lorazepam | 19 | suppressed |
| Tradjenta | Linagliptin | 19 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Prolia | Denosumab | 17 | 11 |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Dayvigo | Lemborexant | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Niacin Er | Niacin | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,689.86 · 174 records | PFIZER INC. | ABRYSVO, AIRSUPRA, AREXVY, Auvelity, BEXSERO, BREZTRI, CAPLYTA, COMIRNATY, Dexcom G6 Transmitter, ELIQUIS, EOHILIA, EVENITY, FANAPT, FARXIGA, Flexitouch Plus, Fluad, Flucelvax, JARDIANCE, JOURNAVX, KRYSTEXXA, Kerendia, Korlym, MOUNJARO, NEXLETOL, NURTEC ODT, Nimbl, OTEZLA, Ozempic, PENBRAYA, PREVNAR 20, PROCLAIM, QULIPTA, REPATHA, REXULTI, Rybelsus, SPRAVATO, TRELEGY ELLIPTA, TZIELD, UBRELVY, UROLIFT, VRAYLAR, Veozah, WAKIX, ZAVZPRET, ZEPBOUND | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error